A mass dog vaccination campaign stops rabies transmission in its tracks

December 20, 2017

Mass dog vaccination campaigns in an African city successfully interrupted rabies transmission for nine months during 2014, researchers report. They say their results show that currently available vaccines can halt the spread of rabies, provided that local communities are informed and engaged. Even though vaccines for dogs work well, more than 59,000 individuals die every year after contracting rabies from a canine. This problem is most severe in Africa and Asia, where some people cannot afford to inoculate their own pets and thus depend on free mass vaccination campaigns. Seeking a better understanding of the social and ecological factors determining whether mass vaccination will be successful, Jakob Zinsstag et al. analyzed rabies transmission in N'Djaména (the capital city of the African nation Chad) after two campaigns that occurred in 2012 and 2013. Both campaigns vaccinated roughly 71% of all dogs in the city during each year, and the scientists' analysis showed that no dogs became newly infected with rabies through November of 2014. What's more, the number of dog-to-human rabies transmissions was less than one per one million people during the nine months following the campaign. Although an earlier than anticipated jump in rabies transmission did occur in N'Djaména after the campaign, analysis of viral genomes indicated that the new cases came into the city from domestic dogs living in semi-urban areas surrounding the capital. The authors suggest that future dog rabies vaccination campaigns should be planned with wider coverage - including suburban and outlying areas - to halt transmission in urban centers.

American Association for the Advancement of Science

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.